General Information of Drug Therapeutic Target (DTT) (ID: TTE0A2F)

DTT Name Dopamine D4 receptor (D4R)
Synonyms DRD4; D(2C)D(4) dopamine receptor dopamine receptor
Gene Name DRD4
DTT Type
Successful target
[1]
BioChemical Class
GPCR rhodopsin
UniProt ID
DRD4_HUMAN
TTD ID
T24983
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MGNRSTADADGLLAGRGPAAGASAGASAGLAGQGAAALVGGVLLIGAVLAGNSLVCVSVA
TERALQTPTNSFIVSLAAADLLLALLVLPLFVYSEVQGGAWLLSPRLCDALMAMDVMLCT
ASIFNLCAISVDRFVAVAVPLRYNRQGGSRRQLLLIGATWLLSAAVAAPVLCGLNDVRGR
DPAVCRLEDRDYVVYSSVCSFFLPCPLMLLLYWATFRGLQRWEVARRAKLHGRAPRRPSG
PGPPSPTPPAPRLPQDPCGPDCAPPAPGLPRGPCGPDCAPAAPSLPQDPCGPDCAPPAPG
LPPDPCGSNCAPPDAVRAAALPPQTPPQTRRRRRAKITGRERKAMRVLPVVVGAFLLCWT
PFFVVHITQALCPACSVPPRLVSAVTWLGYVNSALNPVIYTVFNAEFRNVFRKALRACC
Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells.
KEGG Pathway
Neuroactive ligand-receptor interaction (hsa04080 )
Dopaminergic synapse (hsa04728 )
Reactome Pathway
G alpha (i) signalling events (R-HSA-418594 )
Dopamine receptors (R-HSA-390651 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
2 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clozapine DMFC71L Schizophrenia 6A20 Approved [2]
Phenyltoloxamine DMKAEQW Allergy 4A80-4A85 Approved [1]
------------------------------------------------------------------------------------
4 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [3]
L-745,870 DMTGR25 Psychotic disorder 6A20-6A25 Phase 2 [4]
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [5]
NGD 94-1 DMM1Y8F Schizophrenia 6A20 Phase 1 [6]
------------------------------------------------------------------------------------
8 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
ABT-724 DMDQVY4 Erectile dysfunction HA01.1 Discontinued in Phase 2 [7]
Lu-35138 DMQ7A35 Psychotic disorder 6A20-6A25 Discontinued in Phase 2 [8]
NGD-94-4 DMZ9WLO Schizophrenia 6A20 Discontinued in Phase 1 [9]
A-80426 DMBC3DG N. A. N. A. Terminated [10]
Belaperidone DMM0ZIJ Schizophrenia 6A20 Terminated [6]
BIMG80 DM9X1DZ Psychotic disorder 6A20-6A25 Terminated [11]
Sonepiprazole DMFI0GW Schizophrenia 6A20 Terminated [6]
YM-43611 DMWI094 Psychotic disorder 6A20-6A25 Terminated [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 Discontinued Drug(s)
3 Preclinical Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
PD-165167 DMD0GB4 Schizophrenia 6A20 Preclinical [6]
SPI-376 DMC1WAJ Schizophrenia 6A20 Preclinical [6]
U-99363E DMOIWVC Schizophrenia 6A20 Preclinical [6]
------------------------------------------------------------------------------------
60 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
(+/-)-nantenine DM0L3GE Discovery agent N.A. Investigative [13]
(4-Ethynyl-cyclohex-3-enyl)-dipropyl-amine DMHQCRU Discovery agent N.A. Investigative [14]
(4-Phenylethynyl-cyclohex-3-enyl)-dipropyl-amine DMQM8O5 Discovery agent N.A. Investigative [14]
1-(4-(1H-pyrazol-1-yl)benzyl)-4-phenylpiperazine DMUDVRM Discovery agent N.A. Investigative [15]
1-Benzyl-4-(2-ethynyl-pyrrol-1-yl)-piperidine DMF0GXD Discovery agent N.A. Investigative [16]
1-Benzyl-4-(2-iodo-pyrrol-1-yl)-piperidine DMBRJ5S Discovery agent N.A. Investigative [16]
1-Benzyl-4-(2-oxazol-5-yl-pyrrol-1-yl)-piperidine DMSBNY8 Discovery agent N.A. Investigative [16]
1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine DMCJZVA Discovery agent N.A. Investigative [16]
1-Benzyl-4-pyrrol-1-yl-piperidine DMNWEC9 Discovery agent N.A. Investigative [16]
1-Dibenzo[b,f]oxepin-10-yl-4-methyl-piperazine DMOL2Y0 Discovery agent N.A. Investigative [17]
1-[2-(2-Benzyl-phenoxy)-ethyl]-piperidine DMTNRG7 Discovery agent N.A. Investigative [1]
1-[2-(2-Benzyl-phenoxy)-ethyl]-pyrrolidine DMLSU30 Discovery agent N.A. Investigative [1]
1-[3-(2-Benzyl-phenoxy)-propyl]-pyrrolidine DMD2NXL Discovery agent N.A. Investigative [1]
3-(2-Benzylamino-ethoxy)-phenol DMZCTGF Discovery agent N.A. Investigative [18]
3-(4-Methyl-piperidin-1-ylmethyl)-1H-indole DM0HYDZ Discovery agent N.A. Investigative [19]
3-(4-Phenyl-piperazin-1-ylmethyl)-1H-indole DM17SNR Discovery agent N.A. Investigative [19]
3-(4-Phenyl-piperidin-1-ylmethyl)-1H-indole DMM0WGI Discovery agent N.A. Investigative [19]
4-(2-Benzylamino-ethoxy)-1,3-dihydro-indol-2-one DMYVD2E Discovery agent N.A. Investigative [18]
4-(4-Benzyl-piperazin-1-yl)-1H-benzoimidazole DMXAEW9 Discovery agent N.A. Investigative [20]
4-(4-Benzyl-piperazin-1-yl)-1H-indole DMWR0AS Discovery agent N.A. Investigative [20]
4-(4-Benzyl-piperazin-1-yl)-5-chloro-1H-indole DMZ4237 Discovery agent N.A. Investigative [20]
4-(4-Benzyl-piperazin-1-yl)-7-bromo-1H-indole DMVAB7U Discovery agent N.A. Investigative [20]
4-[2-(2-Benzyl-phenoxy)-ethyl]-morpholine DM08CG7 Discovery agent N.A. Investigative [1]
A-381393 DMI4TVB Discovery agent N.A. Investigative [4]
A-425444 DMM5XD6 Discovery agent N.A. Investigative [21]
A412997 DMKY9G5 Discovery agent N.A. Investigative [22]
ABT-670 DM6J57N Discovery agent N.A. Investigative [21]
Benzyl-[2-(1H-indazol-4-yloxy)-ethyl]-amine DMTC4G0 Discovery agent N.A. Investigative [18]
Benzyl-[2-(1H-indol-4-yloxy)-ethyl]-amine DMV6DY7 Discovery agent N.A. Investigative [18]
CP-226269 DMGLO2X Discovery agent N.A. Investigative [23]
E-1455 DMHPFMV Schizophrenia 6A20 Investigative [24]
FAUC 113 DMC6J3B Discovery agent N.A. Investigative [25]
FAUC213 DM1LMFG Discovery agent N.A. Investigative [23]
FLUMEZAPINE DMW0HOG Discovery agent N.A. Investigative [26]
FLUTROLINE DMUOHVL Discovery agent N.A. Investigative [27]
ISOCLOZAPINE DM52CPU Discovery agent N.A. Investigative [17]
ISOLOXAPINE DMH1BN4 Discovery agent N.A. Investigative [28]
JL-18 DM0LD3F Discovery agent N.A. Investigative [29]
L-741626 DMCYQJF Discovery agent N.A. Investigative [30]
L-741742 DMP75YK Discovery agent N.A. Investigative [31]
L-750,667 DM2WUKF Discovery agent N.A. Investigative [32]
ML398 DMA0E2Q Discovery agent N.A. Investigative [33]
N-(4-Dipropylaminobutyl)-4-biphenylcarboxamide DMU1ATH Discovery agent N.A. Investigative [34]
N-(4-Propylaminobutyl)-4-biphenylcarboxamide DMG9D7A Discovery agent N.A. Investigative [34]
nafadotride DM79KLR Discovery agent N.A. Investigative [32]
PF-592379 DMY93GJ Discovery agent N.A. Investigative [35]
PG-01037 DM2TP4Q Discovery agent N.A. Investigative [36]
piribedil DMNP6QD Discovery agent N.A. Investigative [37]
QUINPIROLE DMDNHEP Discovery agent N.A. Investigative [38]
RBI257 DM9IQXM Discovery agent N.A. Investigative [23]
Ro 10-4548 DMXT34V Discovery agent N.A. Investigative [23]
SB-271046 DM5VJAF Discovery agent N.A. Investigative [39]
STEPHOLIDINE DMGMXQC Discovery agent N.A. Investigative [40]
TKP-1002 DMZU4O8 Schizophrenia 6A20 Investigative [24]
U101958 DM9GOAV Discovery agent N.A. Investigative [41]
UH-232 DM5K6ZE Discovery agent N.A. Investigative [42]
[125I]L750667 DMO7VRJ Discovery agent N.A. Investigative [43]
[2-(1H-Benzoimidazol-4-yloxy)-ethyl]-benzyl-amine DMSPMHE Discovery agent N.A. Investigative [18]
[3H]N-methylspiperone DM5176Y Discovery agent N.A. Investigative [32]
[3H]spiperone DMWHEV8 Discovery agent N.A. Investigative [44]
------------------------------------------------------------------------------------
⏷ Show the Full List of 60 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Schizophrenia 6A20 Pre-frontal cortex 1.53E-01 0.03 0.1
Schizophrenia 6A20 Superior temporal cortex 7.13E-01 0.08 0.4
Parkinson's disease 8A00.0 Substantia nigra tissue 1.90E-01 0.19 0.76
------------------------------------------------------------------------------------

References

1 Dopamine/serotonin receptor ligands. 9. Oxygen-containing midsized heterocyclic ring systems and nonrigidized analogues. A step toward dopamine D5 ... J Med Chem. 2004 Aug 12;47(17):4155-8.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
4 Dopamine D4 receptor involvement in the discriminative stimulus effects in rats of LSD, but not the phenethylamine hallucinogen DOI. Psychopharmacology (Berl). 2009 Apr;203(2):265-77.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
7 Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A. 2004 April 27; 101(17): 6758-6763.
8 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014237)
9 I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor. J Pharmacol Exp Ther. 1997 Aug;282(2):1011-9.
10 Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
11 BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem. 1997 Jul;69(1):182-90.
12 Effects of YM-43611, a novel dopamine D2-like receptor antagonist, on immediate early gene expression in the rat forebrain. Neuropsychopharmacology. 1997 Jul;17(1):27-33.
13 Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
14 Conjugated enynes as nonaromatic catechol bioisosteres: synthesis, binding experiments, and computational studies of novel dopamine receptor agonis... J Med Chem. 2000 Feb 24;43(4):756-62.
15 Synthesis and biological investigations of dopaminergic partial agonists preferentially recognizing the D4 receptor subtype. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2955-9.
16 Piperidinylpyrroles: design, synthesis and binding properties of novel and selective dopamine D4 receptor ligands. Bioorg Med Chem Lett. 1999 Nov 1;9(21):3143-6.
17 Affinity of 10-(4-methylpiperazino)dibenz[b,f]oxepins for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1982 Jul;25(7):855-8.
18 New generation dopaminergic agents. 7. Heterocyclic bioisosteres that exploit the 3-OH-phenoxyethylamine D2 template. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2593-8.
19 3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4... J Med Chem. 1996 May 10;39(10):1941-2.
20 New generation dopaminergic agents. 5. Heterocyclic bioisosteres that exploit the 3-OH-N1-phenylpiperazine dopaminergic template. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2675-80.
21 Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 ago... J Med Chem. 2006 Dec 14;49(25):7450-65.
22 A-412997 is a selective dopamine D4 receptor agonist in rats. Pharmacol Biochem Behav. 2005 Sep;82(1):140-7.
23 Certain 1,4-disubstituted aromatic piperidines and piperazines with extreme selectivity for the dopamine D4 receptor interact with a common recepto... Mol Pharmacol. 2004 Dec;66(6):1491-9.
24 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 217).
25 Comparative molecular field analysis of dopamine D4 receptor antagonists including 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 113), 3-[4-(4-chlorophenyl)piperazin-1-ylmethyl]-1H-pyrrolo-[2,3-b]pyridine (L-745,870), and clozapine. J Med Chem. 2001 Apr 12;44(8):1151-7.
26 Effects of conformationally restricted 4-piperazinyl-10H-thienobenzodiazepine neuroleptics on central dopaminergic and cholinergic systems. J Med Chem. 1982 Oct;25(10):1133-40.
27 Neuroleptic activity in 5-aryltetrahydro-gamma-carbolines. J Med Chem. 1980 Jun;23(6):635-43.
28 Synthesis of clozapine analogues and their affinity for clozapine and spiroperidol binding sites in rat brain. J Med Chem. 1981 Sep;24(9):1021-6.
29 (S)-(-)-4-[4-[2-(isochroman-1-yl)ethyl]-piperazin-1-yl] benzenesulfonamide, a selective dopamine D4 antagonist. J Med Chem. 1996 Jun 21;39(13):2435-7.
30 Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626. Bioorg Med Chem. 2010 Jul 15;18(14):5291-300.
31 5-(4-Chlorophenyl)-4-methyl-3-(1-(2-phenylethyl)piperidin-4-yl)isoxazole: a potent, selective antagonist at human cloned dopamine D4 receptors. J Med Chem. 1996 May 10;39(10):1943-5.
32 Nonconserved residues in the second transmembrane-spanning domain of the D(4) dopamine receptor are molecular determinants of D(4)-selective pharmacology. Mol Pharmacol. 2000 Jan;57(1):144-52.
33 Discovery and Characterization of ML398, a Potent and Selective Antagonist of the D4 Receptor with in Vivo Activity. ACS Med Chem Lett. 2014 Jul 9;5(9):1060-4.
34 Novel D3 selective dopaminergics incorporating enyne units as nonaromatic catechol bioisosteres: synthesis, bioactivity, and mutagenesis studies. J Med Chem. 2008 Nov 13;51(21):6829-38.
35 Lack of abuse potential in a highly selective dopamine D3 agonist, PF-592,379, in drug self-administration and drug discrimination in rats. Behav Pharmacol. 2012 Jun;23(3):280-91.
36 Heterocyclic analogues of N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3... J Med Chem. 2007 Aug 23;50(17):4135-46.
37 Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):791-804.
38 Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of he... J Med Chem. 2005 Sep 8;48(18):5771-9.
39 Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43.
40 Dibenzazecine scaffold rebuilding--is the flexibility always essential for high dopamine receptor affinities Bioorg Med Chem. 2009 Oct 1;17(19):6898-907.
41 Substituted 4-aminopiperidines having high in vitro affinity and selectivity for the cloned human dopamine D4 receptor. Eur J Pharmacol. 1997 Mar 19;322(2-3):283-6.
42 (Dipropylamino)-tetrahydronaphthofurans: centrally acting serotonin agonists and dopamine agonists-antagonists, Bioorg. Med. Chem. Lett. 7(21):2759-2764 (1997).
43 Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor. Mol Pharmacol. 1996 Dec;50(6):1658-64.
44 Differential effects of [3H]nemonapride and [3H]spiperone binding on human dopamine D4 receptors. Neurosci Lett. 1995 Feb 17;186(2-3):145-8.